Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery

• DOI: 10.1186/s12876-018-0871-2
• Publication Date: 2018-10-03T10:58:08Z
• Authors: Xianwen Yuan; Jun Chen; Qi Cheng; Yinjuan Zhao; Pengzi Zhang; Xiaoyan Shao; Yan Bi; Xiaolei Shi; Yitao Ding; Xitai Sun; Bin Xue
• Keywords: Bariatric surgery; Adult; Male; 0301 basic medicine; Bariatric Surgery; Yin Yang 1(YY1); RC799-869; Diseases of the digestive system. Gastroenterology; Middle Aged; Obesity, Morbid; 3. Good health; Non-alcoholic fatty liver disease (NAFLD); Young Adult; 03 medical and health sciences; Liver; Non-alcoholic Fatty Liver Disease; Disease Progression; Humans; Female; RNA, Messenger; YY1 Transcription Factor; Research Article

This study is to investigate the association between the hepatic expression of Yin Yang 1 (YY1) and the progression of non-alcoholic fatty liver disease (NAFLD) in patients undergoing bariatric surgery.Obese patients undergoing bariatric surgery were included. Liver tissues were subjected to the quantitative real-time PCR, Western blot analysis, and immunohistochemical assay, to determine the expression levels of YY1.Totally 88 patients were included. According to the NAFLD activity score (NAS), these patients were divided into the control (n = 12), steatosis (n = 20), non-defining NASH (n = 38), and NASH (n = 18) groups. Significant differences in the serum glucose, insulin, ALT, AST, and HOMA-IR levels were observed among these different NAFLD groups. Hepatic YY1 expression had correlation with serum glucose, insulin, HOMA-IR, ALT, AST, triglycerides, HDL, and GGT. Immunohistochemical analysis showed that, compared with the control group, the expression levels of YY1 were significantly higher in the non-defining NASH and NASH groups. In addition, multivariate regression model showed that the serum ALT and YY1 levels were strongly associated with the NAFLD activity.Several factors are associated with NAFLD progression, including the expression of YY1. Our findings contribute to understanding of the pathogenesis of NAFLD.NCT03296605 , registered on September 28, 2017.